Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial

– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –

– Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated –

Read more at globenewswire.com